Cellexus

Cellexus

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $750K

Overview

Cellexus is a private biotechnology equipment company founded in 2015 and headquartered in Cambridge, UK, specializing in innovative single-use airlift bioreactors. Its core technology, the CellMaker system, offers a unique method of aeration and mixing aimed at improving cell growth, yield, and process simplicity while reducing contamination risk. The company serves the cell therapy and biologics sectors, providing equipment and custom solutions from early-stage research to scale-up, and is in a revenue-generating stage with a direct sales and support business model.

Cell TherapyBiologics

Technology Platform

Single-use airlift bioreactor systems (CellMaker) for gentle, low-shear mixing and aeration in cell culture and fermentation processes.

Funding History

2
Total raised:$750K
Grant$250K
Seed$500K

Opportunities

The rapid growth of cell and gene therapies, viral vector manufacturing, and bacteriophage production creates strong demand for gentle, single-use bioreactor systems.
The industry-wide shift towards flexible and decentralized manufacturing further favors compact, easy-to-use platforms like the CellMaker.

Risk Factors

Faces intense competition from large, established bioprocessing equipment giants with broader portfolios.
Technology adoption may be limited if the airlift principle is not accepted for large-scale commercial manufacturing beyond niche applications.
Scalability of the platform beyond 50L presents a significant technical and commercial challenge.

Competitive Landscape

Competes against major players in single-use bioreactors like Sartorius, Thermo Fisher Scientific, Cytiva (Danaher), and Merck Millipore, which primarily offer stirred-tank systems. Cellexus differentiates through its airlift technology, emphasizing low-shear mixing, simplicity, and reduced contamination risk for specific sensitive cell culture applications.